MONSEY, N.Y., June 24, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera") to ANI Pharmaceuticals ("ANI") for $5.50 per share in cash, plus a contingent value right (CVR) of $0.50 per share upon the achievement of certain net revenue milestones. The cash component of the sales price is below the price target for Alimera of (i) $10.00 per share of Maxim Group analyst Naz Rahman, and (ii) $6.00 per share of H.C. Wainwright analyst Yi Chen (source: TipRanks).
If you remain an Alimera shareholder and question the fairness of the price, you may contact our firm at the following link to discuss your legal rights at no charge:
https://wohlfruchter.com/cases/alimera-sciences/
Alternatively, you may contact us by phone ...